Literature DB >> 2576302

Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA.

R Gollamudi1, S F Ali, G Lipe, G Newport, P Webb, M Lopez, J E Leakey, M Kolta, W Slikker.   

Abstract

(S)-(+)- and (R)-(-)-3,4-methylenedioxymethamphetamine (MDMA) were metabolized in vitro by rat liver microsomes via N-demethylation to 3,4-methylenedioxyamphetamine (MDA). Whereas no difference was found in the biotransformation of the two enantiomers in the male rat or in the phenobarbital (PB) treated animals of either sex, more than twice as much MDA was formed from (S)-(+)- than from (R)-(-)-MDMA in the untreated female rat. Although 3-methylcholanthrene (3MC) pretreated rat liver microsomes were less active than those from the untreated rats of the same sex, they formed more MDA from (+)- than from (-)-MDMA. The enantioselective metabolism thus appears to be associated with the relative abundance of individual cytochrome P-450 isozymes. (S)-(+)- and (R)-(-)-MDMA.HCl (20 mg/kg) were about equipotent in depleting serotonin (5-HT) levels in the frontal cortex at 3 hrs and 1 wk following oral administration to female rats. Pretreatment of rats with SKF-525A attenuated and that with PB enhanced the 5-HT depleting potential of either isomer at 3 hrs. The 5-HT depleting potency of (+)-MDMA was significantly greater than that of its (-)-antipode at 3 hr in PB pretreated, but not in SKF-525A pretreated animals. The results suggest that the neurochemical effects of MDMA are caused by the formation of an active metabolite in vivo, and since both enantiomers were N-demethylated in vitro to approximately the same extent by PB pretreated rat liver microsomes, the active metabolite may be other than MDA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2576302

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  10 in total

1.  Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Biochem Pharmacol       Date:  2011-09-29       Impact factor: 5.858

2.  Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Clin Chem       Date:  2011-10-06       Impact factor: 8.327

3.  Inhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine formation but no change in serotonin neurotoxicity: implications for mechanisms of neurotoxicity.

Authors:  Melanie Mueller; Jie Yuan; Concepcion Maldonado Adrian; Una D McCann; George A Ricaurte
Journal:  Synapse       Date:  2011-03-28       Impact factor: 2.562

4.  Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes.

Authors:  Daniel José Barbosa; João Paulo Capela; Jorge Ma Oliveira; Renata Silva; Luísa Maria Ferreira; Filipa Siopa; Paula Sério Branco; Eduarda Fernandes; José Alberto Duarte; Maria de Lourdes Bastos; Félix Carvalho
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  Ecstasy metabolites and monoamine neurotransmitters upshift the Na+/K+ ATPase activity in mouse brain synaptosomes.

Authors:  Daniel José Barbosa; João Paulo Capela; Luísa Maria Ferreira; Paula Sério Branco; Eduarda Fernandes; Maria de Lourdes Bastos; Félix Carvalho
Journal:  Arch Toxicol       Date:  2022-09-14       Impact factor: 6.168

6.  Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Authors:  Melanie Mueller; Jie Yuan; Anne Felim; Anne Neudörffer; Frank T Peters; Hans H Maurer; Una D McCann; Martine Largeron; George A Ricaurte
Journal:  Drug Metab Dispos       Date:  2009-07-23       Impact factor: 3.922

7.  Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage.

Authors:  Melanie Mueller; Frank T Peters; Marilyn A Huestis; George A Ricaurte; Hans H Maurer
Journal:  Forensic Sci Int       Date:  2009-01-07       Impact factor: 2.395

8.  The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.

Authors:  M I Colado; J L Williams; A R Green
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

9.  Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in squirrel monkey plasma.

Authors:  Melanie Mueller; Frank T Peters; George A Ricaurte; Hans H Maurer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-07-06       Impact factor: 3.205

10.  Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.

Authors:  Andrea E Steuer; Corina Schmidhauser; Eva H Tingelhoff; Yasmin Schmid; Anna Rickli; Thomas Kraemer; Matthias E Liechti
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.